| 摘要 |
<p>The present invention relates to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are Δ-5-androstene-17α-ol, androstane-17α-ol-pregnane-17α-ol or pregnane-17α-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3ß,17α-diol or androstane-3ßα-diol, an enzyme and a sulfotransferase to provide 5-androstene-17α-ol-3ß-sulfate or corresponding androstane derivative (17α-AEDS or 17-AADS); and mixing the 17α-AEDS or 17α-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to perox-isome proliferator-activated receptor-η (PPARη) is produced.</p> |
